Get the Stockscreener App
5.69
4.07%
-0.3664
Molecular Partners Ag Adr stock is traded at $5.69, with a volume of 4,268.
It is down -4.07% in the last 24 hours and up +15.74% over the past month.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
See More
Previous Close:
$6.0564
Open:
$5.76
24h Volume:
4,268
Relative Volume:
0.18
Market Cap:
$212.18M
Revenue:
$7.80M
Net Income/Loss:
$-69.02M
P/E Ratio:
-2.8213
EPS:
-2.0168
Net Cash Flow:
$-66.61M
1W Performance:
-6.29%
1M Performance:
+15.74%
6M Performance:
+45.98%
1Y Performance:
+25.76%
1-Day Range:
$5.67
$5.84
1-Week Range:
$5.30
$6.25
52-Week Range:
$3.32
$12.70
Molecular Partners Ag Adr Stock (MOLN) Company Profile
Name
Molecular Partners Ag Adr
Sector
Industry
Phone
-
Address
-
Molecular Partners Ag Adr Stock (MOLN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-30-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-29-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-25-22 | Upgrade | Credit Suisse | Underperform → Neutral |
| Apr-27-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-12-21 | Resumed | SVB Leerink | Outperform |
View All
Molecular Partners Ag Adr Stock (MOLN) Latest News
Molecular Partners backs FY24 total expenses view of of CHF 65M-CHF 70M - TipRanks
Molecular Partners, Orano Med announce presentation of MP0712 data - TipRanks
Molecular Partners expands 212Pb co-development agreement with Orano Med - TipRanks
Molecular Partners shares gain on Leerink's outperform rating - Investing.com
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket - Benzinga
Wall Street Analysts See a 96% Upside in Molecular Partners AG Sponsored ADR (MOLN): Can the Stock Really Move ... - Yahoo News UK
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit - GlobeNewswire Inc.
Molecular Partners' New Therapy Shows AML Treatment PromiseTipRanks.com - TipRanks
Molecular Partners Unveils Promising Cancer Therapy - TipRanks
Why GameStop Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket By Benzinga - Investing.com UK
Molecular Partners Shares Rise on Positive Trial Data for MP0317 - MarketWatch
Novartis (NVS) & Molecular Partners Initiate Study for COVID-19 - Yahoo Singapore News
Rigel Pharmaceuticals names new Chief Medical Officer By Investing.com - Investing.com
Molecular Partners: Sellers Have Disappeared, Enterprise Value Below Zero (NASDAQ:MOLN) - Seeking Alpha
U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.19% - Investing.com UK
US stock market gainers for the last week of April 2022 - Nairametrics
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.45% - Investing.com India
The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOsiShares Biote - Benzinga
Molecular Partners (MLLCF) Stock Price, News & Analysis - MarketBeat
Market Data Center - Barron's
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Molecular Partners Ag Adr Stock (MOLN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):